Drug Discovery & Development
Monash’s drug discovery and development capabilities span the entire pipeline — from identifying new drug targets and designing molecules through to optimisation, delivery, and evaluation. These open-access platforms and facilities bring together world-leading expertise in medicinal chemistry, pharmacology, formulation, and analytics, enabling seamless progression from fundamental science to translational outcomes.
Our capabilities support innovation across:
- Novel medicines - uncovering and validating drug targets for neurological, cardiovascular, metabolic, infectious, and mental health conditions.
- Therapeutic innovation - advancing next-generation approaches such as mRNA vaccines, nanomedicines, and antibody-based therapies.
- Translation and impact - progressing candidates into clinical development and partnering with industry, government, and global health organisations.
Monash Capabilities
Animal Research
Supports research with high-quality animal supply, reproductive services, and specialised veterinary expertise.
Antibody Discovery
Provides services for antibody discovery, production and sequencing, cell line cryopreservation and ELISA development.
Australian Translational Medicinal Chemistry Facility
A collaborative hub bridging early-stage biology with drug discovery and pre-clinical development.
Biomedical Imaging
Provides multimodal imaging, human testing, and animal support with full services from ethics to data analysis.
Cryo Electron Microscopy
Provides expertise in advanced electron microscopy for biomedical discoveries at molecular and cellular level.
Drug Candidate Optimisation
Provides expertise in advanced electron microscopy for biomedical discoveries at molecular and cellular level.
Drug Target Identification
A custom designed, state of the art facility for precise protein and metabolite identification, characterisation and analysis.
Flowcore
Delivers advanced flow cytometry services to characterise cells and particles of interest.
Fragment Drug Design
Provides access to fragment-based drug discovery and DNA encoded library technologies for small molecule drug development.
Functional Genomics
Provides the tools and expertise for unbiased, systematic, high-throughput gain-of-function and loss-of-function screens in human and mouse cells.
Genome Modification
Provides a comprehensive service in animal and cell genome modification as well as DNA construct design and production.
Genomics and Bioinformatics
Offers cutting-edge sequencing technologies and bioinformatics expertise to support research and training.
HMSTrust Laboratory
Provides advanced physical and chemical characterisation to support modern drug development.
Macromolecular Crystallisation
Specialises in high-throughput crystallisation to reveal 3D structures of biological macromolecules.
Medicines Manufacturing Innovation Centre
Supports pharmaceutical innovation through expert formulation, analytical services, and workforce training.
Proteomics and Metabolomics
Utilises state-of-the-art methodologies to provide comprehensive services across proteomics, metabolomics, lipidomics, immunopeptidomics, and N-terminal sequencing.
National Capabilities
Phenomics Australia
Phenomics Australia enables research discovery with high-impact health outcomes. It offers capabilities in disease modelling (in vivo & in vitro), biobanking, genome engineering, and supports precision medicine.
Therapeutic Innovation Australia
Therapeutic Innovation Australia (TIA) enables and accelerates translation of research discoveries through the therapeutic development pipeline.